Stockscreener 앱 받기
257.41
2.24%
-5.89
시장 영업 전:
257.85
0.44
+0.17%
전일 마감가:
$263.30
열려 있는:
$258.38
하루 거래량:
6.40M
Relative Volume:
0.95
시가총액:
$454.79B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
126.97
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
+0.19%
1개월 성능:
+1.22%
6개월 성능:
+15.43%
1년 성능:
+35.97%
1일 변동 폭
$253.51
$259.89
1주일 범위
$253.51
$267.47
52주 변동 폭
$187.62
$267.47
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis - TradingKey
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating - marketscreener.com
Should You Buy AbbVie Stock Hand Over Fist Before July 31? - The Motley Fool
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
AbbVie Researcher Dr. Jan Stoehr Outlines Use of Biomarkers to Target Parkinson’s Disease Progression - geneonline.com
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
AbbVie stock hits all-time high of 261.71 USD - Investing.com
Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet - TIKR.com
How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing - Stock Traders Daily
AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant With A Promising 3.25% Upside - DirectorsTalk Interviews
ABBV|AbbVie Inc|Price:265.610|Chg%:+8.700 - TradingKey
AbbVie Inc Agencies, 2026 - OpenSecrets
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? - The Motley Fool
AbbVie stock steadies as investors weigh Humira erosion against Skyrizi and Rinvoq growth - Ad-hoc-news.de
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback - Yahoo Finance
AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth - AD HOC NEWS
Should You Pay Attention To AbbVie Stock's Momentum? - Trefis
AbbVie stock may move 4.2% on July 31 earnings report By Investing.com - Investing.com Nigeria
AbbVie stock may move 4.2% on July 31 earnings report - Investing.com
AbbVie: A Dividend Fortress At An Appealing Price Tag - Seeking Alpha
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint - GuruFocus
AbbVie, Genmab post trial setback for lymphoma drug (ABBV:NYSE) - Seeking Alpha
CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras SystemsNetflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS - Benzinga
AbbVie stock trades steadily as investors weigh Skyrizi and Rinvoq growth against Humira erosion - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV) - The Globe and Mail
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint - Stock Titan
AbbVie: Bright Future, But Already Priced In (NYSE:ABBV) - Seeking Alpha
Donald TrumpABBVIE INC COM UNSOLICITED Trump Trade on Mar. 25, 2026 - Quiver Quantitative
AbbVie stock holds near record levels after second-quarter results - Ad-hoc-news.de
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Total equity of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs - Bloomberg Law News
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2? - TradingView
Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating - marketscreener.com
Canaccord raises Abbvie stock price target to $282 on growth outlook - Investing.com
ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana - GuruFocus
ETFs Investing in AbbVie, Inc. Stocks - TradingView
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애브비 주식 (ABBV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
0.44%
0.06%
자본화:
|
볼륨(24시간):